Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring

LeonaBio, Inc.

Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.
Completed enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer's; topline data expected H2 2024.
Plans to initiate first-in-human studies of ATH-1105 for ALS in H1 2024.
CMO Hans Moebius retired effective Jan 5, 2024; will serve as Senior Scientific Advisor through March 31 transition period.
Over 60 patients continue fosgonimeton treatment beyond 18 months in open-label extension.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Hans Moebius

Senior Scientific Advisor

LONA · LeonaBio, Inc.

Effective: 2024-01-05
Filed: January 8, 2024, 6:59 PM ET

Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hans Moebius changed role as Senior Scientific Advisor at LeonaBio, Inc..

Role: Senior Scientific Advisor

Exact text from the filing

Dr. Moebius voluntarily resigned his position as CMO effective January 5, 2024, and will continue employment on an at-will basis for a transition period ending March 31, 2024 (the “Transition Period”). During the Transition Period, Dr. Moebius will serve as a full-time employee in the role of Senior Scientific Advisor reporting to the Company’s Chief Executive Officer.

View on SEC.gov

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-002686

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.